ALX Oncology Holdings Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-18.0M | $-17.9M | $-22.8M | $-22.1M | $-25.9M | $-30.8M | $-29.2M | $-30.7M |
| Depreciation & Amortization | $100.0K | $150.0K | $95.0K | $200.0K | $200.0K | $211.0K | $258.0K | $200.0K |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $2.7M | $2.5M | $2.7M | $2.5M | $2.1M | $5.2M | $5.9M | $7.0M |
| Net Cash from Operating Activities | $-16.1M | $-18.6M | $-19.0M | $-17.1M | $-23.4M | $-24.7M | $-32.0M | $-25.4M |
| Investing Activities | ||||||||
| Capital Expenditures | $17.0K | $50.0K | $49.0K | $56.0K | $47.0K | $60.0K | $60.0K | $149.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $6.5M | $-105.0M | $11.2M | $21.4M | $22.3M | $27.6M | $33.2M | $25.7M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $137.0K | $139.6M | $678.0K | $-159.0K | $-222.0K | $65.0K | $328.0K | $251.0K |
| Net Change in Cash | — | — | — | — | — | — | — | — |
| Free Cash Flow | $-16.1M | $-18.7M | $-19.0M | $-17.1M | $-23.5M | $-24.7M | $-32.1M | $-25.5M |